|
|
|
|
|
|
|
|
|
|
The Lancet Oncology
A final appraisal determination was issued.7 Stakeholders were given the opportunity to request changes to the document or to appeal against its recommendations. No appeals were received and the guidance was published by NICE on May 22, 2013.
References
1 . Technology
appraisal guidance TA284. Bevacizumab in combination with paclitaxel
and carboplatin for first-line treatment of advanced ovarian cancer. http://guidance.nice.org.uk/TA284. May, (accessed May 22, 2013).
2 . Single
technology appraisal: bevacizumab in combination with carboplatin and
paclitaxel for the treatment of advanced ovarian cancer. http://www.nice.org.uk/nicemedia/live/13334/62105/62105.pdf. August, (accessed May 8, 2013).
3 . Bevacizumab
in combination with carboplatin and paclitaxel for the first-line
treatment of ovarian cancer. Southampton Health Technology Assessment
Centre. http://www.nice.org.uk/nicemedia/live/13334/62103/62103.pdf. October, (accessed May 8, 2013).
4 . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483. CrossRef | PubMed
5 . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496. CrossRef | PubMed
6 . Ovarian cancer (metastatic)—bevacizumab (with paclitaxel and carboplatin): appraisal consultation document. http://guidance.nice.org.uk/TA/Wave25/16/Consultation/DraftGuidance. December, (accessed May 8, 2013).
7 . Final
appraisal determination: bevacizumab in combination with paclitaxel and
carboplatin for first-line treatment of advanced ovarian cancer. http://www.nice.org.uk/nicemedia/live/13334/63284/63284.pdf. March, (accessed May 8, 2013).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.